نتایج جستجو برای: voriconazole

تعداد نتایج: 2934  

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008
Dimitrios I Zonios Juan Gea-Banacloche Richard Childs John E Bennett

As part of a prospective natural history cohort study of voriconazole toxicity, we describe the characteristics of 12 of 72 voriconazole-treated patients who experienced hallucinations from March 2006 through November 2007. Hallucinations associated with voriconazole use are not uncommon. Doctors should be aware of this complication, and the recipients of the drug should be reassured that the h...

Journal: :Journal of clinical microbiology 2005
Joanna M Schaenman Daniel B DiGiulio Laurence F Mirels Nancy M McClenny Gerald J Berry Annette W Fothergill Michael G Rinaldi Jose G Montoya

An immunocompromised patient with an invasive soft tissue infection due to Scedosporium apiospermum was successfully treated with voriconazole and surgical debridement. After transition from intravenous to oral therapy, successive adjustments of the oral dose were required to achieve complete resolution. For soft tissue infections due to molds characterized by thin, septate hyphae branching at ...

Journal: :Medical mycology 2010
L Van Waeyenberghe K Baert F Pasmans P van Rooij T Hellebuyck L Beernaert P de Backer F Haesebrouck A Martel

Dermal and systemic infections caused by the Chrysosporium anamorph of Nannizziopsis vriesii (CANV) are highly prevalent in reptiles and may result in severe disease and high mortality. Due to the high incidence of therapeutic failures, optimizing treatment is required. We first determined in this study the minimal inhibitory concentrations (MIC) of itraconazole, voriconazole, amphotericin B an...

Journal: :The Journal of infectious diseases 2012
Adam R Jeans Susan J Howard Zaid Al-Nakeeb Joanne Goodwin Lea Gregson Jayesh B Majithiya Cornelia Lass-Flörl Manuel Cuenca-Estrella Maiken C Arendrup Peter A Warn William W Hope

BACKGROUND Voriconazole is a first-line agent for the treatment of invasive pulmonary aspergillosis (IPA). There are increasing reports of Aspergillus fumigatus isolates with reduced susceptibility to voriconazole. METHODS An in vitro dynamic model of IPA was developed that enabled simulation of human-like voriconazole pharmacokinetics. Galactomannan was used as a biomarker. The pharmacodynam...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014
Kiyanna Williams Matthew Mansh Peter Chin-Hong Jonathan Singer Sarah Tuttleton Arron

This article synthesizes the current data regarding the implication of voriconazole in the development of skin cancer in organ transplant recipients (OTRs) and offers suggestions for additional research. According to Organ Procurement and Transplantation Network data, 28 051 solid organ transplants were performed in 2012. Due to advancements in immunosuppression and management of infectious dis...

Journal: :Archives of ophthalmology 2008
G Atma Vemulakonda Seenu M Hariprasad William F Mieler Randall A Prince Gaurav K Shah Russell N Van Gelder

OBJECTIVE To determine the penetration of 1% voriconazole solution into the aqueous and vitreous following topical administration. METHODS A prospective nonrandomized study of 13 patients scheduled for pars plana vitrectomy surgery. Aqueous and vitreous samples were obtained and analyzed after topical administration of 1% voriconazole every 2 hours for 24 hours before surgery. Drug concentrat...

Journal: :Antimicrobial agents and chemotherapy 2013
William W Hope Michael Vanguilder J Peter Donnelly Nicole M A Blijlevens Roger J M Brüggemann Roger W Jelliffe Michael N Neely

The efficacy of voriconazole is potentially compromised by considerable pharmacokinetic variability. There are increasing insights into voriconazole concentrations that are safe and effective for treatment of invasive fungal infections. Therapeutic drug monitoring is increasingly advocated. Software to aid in the individualization of dosing would be an extremely useful clinical tool. We develop...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2003
S J Roffey S Cole P Comby D Gibson S G Jezequel A N R Nedderman D A Smith D K Walker N Wood

Voriconazole is a new triazole antifungal agent with potent, wide-spectrum activity. Its pharmacokinetics and metabolism have been studied in mouse, rat, rabbit, dog, guinea pig, and humans after single and multiple administration by both oral and intravenous routes. Absorption of voriconazole is essentially complete in all species. The elimination of voriconazole is characterized by non-linear...

Journal: :Diagnostic microbiology and infectious disease 2011
Michael A Pfaller David Andes Maiken C Arendrup Daniel J Diekema Ana Espinel-Ingroff Barbara D Alexander Steven D Brown Vishnu Chaturvedi Cynthia L Fowler Mahmoud A Ghannoum Elizabeth M Johnson Cynthia C Knapp Mary R Motyl Luis Ostrosky-Zeichner Thomas J Walsh

We reassessed the Clinical and Laboratory Standards Institute (CLSI) clinical breakpoints (CBPs) for voriconazole. We examined i) the essential (EA: ±2 dilutions) and categorical agreement between 24-h CLSI and EUCAST methods for voriconazole testing of Candida, ii) wild-type (WT) MICs and epidemiologic cutoff values (ECVs) for voriconazole by both CLSI and EUCAST methods, and iii) correlation ...

Journal: :The Turkish journal of pediatrics 2011
Ozden Turan Ebru Ergenekon I Murat Hirfanoğlu E Esra Onal V Nijat Baş Canan Türkyilmaz Esin Koç Yildiz Atalay

The purpose of this article is to report our experience with intravenous voriconazole therapy in the treatment of persistent Candida septicemia in very low birth weight (VLBW) neonates. Candidiasis was defined if an infant had a positive blood culture. Ten VLBW newborns developed Candida sepsis, and candidemia persisted in 6 of them despite 3 to 21 days of antifungal therapy with amphotericin B...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید